sabato, 8 agosto 2026

Notizie AIOM – anno XIV n. 610

20 Dicembre 2016

Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer

Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of ...
Leggi tutto

20 Dicembre 2016

Facilitating Teamwork in Adolescent and Young Adult Oncology

A case of a young adult patient in the days immediately after a cancer diagnosis illustrates the critical importance of three interrelated core coordinating mechanisms - closed-loop communication, shared mental models, and mutual trust—of teamwork in an adolescent ...
Leggi tutto

20 Dicembre 2016

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial

To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus ...
Leggi tutto

20 Dicembre 2016

12 dicembre 2016 – Riunione Comitato Prezzi e Rimborso (CPR)

20 Dicembre 2016

ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers

15 Dicembre 2016 - As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations ...
Leggi tutto

20 Dicembre 2016

EC Approves Ofatumumab Combo in Relapsed CLL

13 Dicembre 2016 - The European Commission (EC) has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for adult patients with relapsed chronic lymphocytic leukemia (CLL), according to Genmab, which codevelops the anti-CD20 antibody with ...
Leggi tutto

20 Dicembre 2016

16 dicembre 2016 – Chiarimenti in merito all’abolizione della Nota 40

20 Dicembre 2016

16 dicembre 2016 – Direttore Generale AIFA in audizione presso il Comitato Nazionale per la Bioetica: nostro dovere garantire a tutti un accesso equo ai farmaci

20 Dicembre 2016

CHMP Recommends Approval of Alectinib for ALK+ NSCLC

16 Dicembre 2016 - The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) following progression on crizotinib, according to Roche, the ...
Leggi tutto

20 Dicembre 2016

Frontline Pembrolizumab Receives Positive CHMP Opinion for PD-L1+

16 Dicembre 2016 - The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations. The application, ...
Leggi tutto